Therapeutic Potential of Ginkgolic Acid C17:1 in Modulating PTEN/mtDNA/TLR9 Axis for Alleviating Chronic Pseudomonas aeruginosa Infection in Bronchiectasis
نویسندگان
doi
10.30498/ijb.2026.567525.4342چکیده
Background: Pseudomonas aeruginosa (PA) colonization drives persistent infection and inflammation in bronchiectasis, a condition lacking targeted biotherapies. Phosphatase and tensin homolog (PTEN) is a key regulator of immune homeostasis, and its plant-derived activator, Ginkgolic acid C17:1 (GAC 17:1), has emerged as a potential biotechnological therapeutic agent due to its anti-inflammatory properties. Objectives: This study aimed to investigate the therapeutic potential of GAC 17:1, a natural compound, in alleviating PA-induced airway injury by targeting the PTEN/mtDNA/TLR9 axis, thereby evaluating its role as a novel biotechnological intervention for immune modulation in bronchiectasis. Methods: A rat model of chronic PA-induced bronchial injury was established and divided into four groups: Control, PA-infected, PA-infected + GAC 17:1 (PTEN activator, 2 mg/kg), and PA-infected + SF1670 (PTEN inhibitor, 1.5 mg/kg). Lung pathology, function (FEV₀.₃, FVC, PEF), PTEN/TLR9/NF-κB expression (RT-qPCR, Western blot), mtDNA content, cytokine levels (IL-6, IL-17, TGF-β; ELISA), and Th17/Treg cell proportions (flow cytometry) were assessed. Results: PA infection downregulated PTEN, elevated mtDNA/TLR9/NF-κB, increased IL-6/IL-17 and Th17 cells, reduced TGF-β and Tregs, and impaired lung function. Treatment with GAC 17:1, the plant-derived PTEN activator, effectively restored PTEN expression, suppressed mtDNA release and TLR9/NF-κB signaling, rebalanced Th17/Treg immunity, reduced inflammatory cytokines, and significantly improved pulmonary function. Conversely, PTEN inhibition worsened all parameters. Conclusions: This study demonstrates that GAC 17:1, a natural bioactive compound, exerts potent significant effects in PA-related bronchiectasis by activating PTEN and inhibiting the mtDNA/TLR9/NF-κB pathway. Our findings highlight GAC 17:1 as a promising biotechnological candidate for developing plant-derived immunomodulatory therapies against chronic airway infections.